Clinical trial
Phase II Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
NCT01605305 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2008
- Completion date
- January 31, 2012
- Enrollment
- 60 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.